Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 1768


Varicella-zoster virus inhibits autophagosome-lysosome fusion and the degradation stage of mTOR-mediated autophagic flux.

Graybill C, Morgan MJ, Levin MJ, Lee KS.

Virology. 2018 Sep;522:220-227. doi: 10.1016/j.virol.2018.07.018. Epub 2018 Jul 24.


mTORC1 and mTORC2 Expression Levels in Oral Squamous Cell Carcinoma: An Immunohistochemical and Clinicopathological Study.

Kawasaki G, Naruse T, Furukawa K, Umeda M.

Anticancer Res. 2018 Mar;38(3):1623-1628.


mTOR signaling in stem and progenitor cells.

Meng D, Frank AR, Jewell JL.

Development. 2018 Jan 8;145(1). pii: dev152595. doi: 10.1242/dev.152595. Review.


mTOR-Dependent Cell Proliferation in the Brain.

Ryskalin L, Lazzeri G, Flaibani M, Biagioni F, Gambardella S, Frati A, Fornai F.

Biomed Res Int. 2017;2017:7082696. doi: 10.1155/2017/7082696. Epub 2017 Nov 13. Review.


Mammalian target of rapamycin signaling is a mechanistic link between increased endoplasmic reticulum stress and autophagy in the placentas of pregnancies complicated by growth restriction.

Hung TH, Hsieh TT, Wu CP, Li MJ, Yeh YL, Chen SF.

Placenta. 2017 Dec;60:9-20. doi: 10.1016/j.placenta.2017.10.001. Epub 2017 Oct 9.


mTOR intersects antibody-inducing signals from TACI in marginal zone B cells.

Sintes J, Gentile M, Zhang S, Garcia-Carmona Y, Magri G, Cassis L, Segura-Garzón D, Ciociola A, Grasset EK, Bascones S, Comerma L, Pybus M, Lligé D, Puga I, Gutzeit C, He B, DuBois W, Crespo M, Pascual J, Mensa A, Aróstegui JI, Juan M, Yagüe J, Serrano S, Lloreta J, Meffre E, Hahne M, Cunningham-Rundles C, Mock BA, Cerutti A.

Nat Commun. 2017 Nov 13;8(1):1462. doi: 10.1038/s41467-017-01602-4.


Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.

Le Rhun E, Bertrand N, Dumont A, Tresch E, Le Deley MC, Mailliez A, Preusser M, Weller M, Revillion F, Bonneterre J.

Eur J Cancer. 2017 Dec;87:189-198. doi: 10.1016/j.ejca.2017.10.006. Epub 2017 Nov 2.


mTOR: A Key to Both Pulmonary Vessel Remodeling and Right Ventricular Function in Pulmonary Arterial Hypertension?

Houssaini A, Adnot S.

Am J Respir Cell Mol Biol. 2017 Nov;57(5):509-511. doi: 10.1165/rcmb.2017-0245ED. No abstract available.


High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.

Khanna A, Bhushan B, Chauhan PS, Saxena S, Gupta DK, Siraj F.

Clin Exp Med. 2018 May;18(2):221-227. doi: 10.1007/s10238-017-0478-x. Epub 2017 Oct 26.


mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.

Orr-Asman MA, Chu Z, Jiang M, Worley M, LaSance K, Koch SE, Carreira VS, Dahche HM, Plas DR, Komurov K, Qi X, Mercer CA, Anthony LB, Rubinstein J, Thomas HE.

Mol Cancer Ther. 2017 Nov;16(11):2432-2441. doi: 10.1158/1535-7163.MCT-17-0058. Epub 2017 Sep 1.


Cap-independent translation ensures mTOR expression and function upon protein synthesis inhibition.

Marques-Ramos A, Candeias MM, Menezes J, Lacerda R, Willcocks M, Teixeira A, Locker N, Romão L.

RNA. 2017 Nov;23(11):1712-1728. doi: 10.1261/rna.063040.117. Epub 2017 Aug 18.


mTOR Signaling Confers Resistance to Targeted Cancer Drugs.

Guri Y, Hall MN.

Trends Cancer. 2016 Nov;2(11):688-697. doi: 10.1016/j.trecan.2016.10.006. Epub 2016 Nov 4. Review.


Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.

Audet-Walsh É, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, Vernier M, Caron M, Bourque G, Scarlata E, Hamel L, Brimo F, Aprikian AG, Lapointe J, Chevalier S, Giguère V.

Genes Dev. 2017 Jun 15;31(12):1228-1242. doi: 10.1101/gad.299958.117. Epub 2017 Jul 19.


mTORC2 regulates hedgehog pathway activity by promoting stability to Gli2 protein and its nuclear translocation.

Maiti S, Mondal S, Satyavarapu EM, Mandal C.

Cell Death Dis. 2017 Jul 13;8(7):e2926. doi: 10.1038/cddis.2017.296.


Targeting the mTOR pathway in breast cancer.

Liu J, Li HQ, Zhou FX, Yu JW, Sun L, Han ZH.

Tumour Biol. 2017 Jun;39(6):1010428317710825. doi: 10.1177/1010428317710825. Review.


mTOR-mediated Na+/Ca2+ exchange affects cell proliferation and metastasis of melanoma cells.

Yang Y, Luo Z, Hao Y, Ba W, Wang R, Wang W, Ding X, Li C.

Biomed Pharmacother. 2017 Aug;92:744-749. doi: 10.1016/j.biopha.2017.05.104. Epub 2017 Jun 4.


An Anti-Cancer Drug Candidate OSI-027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms.

Rehan M.

J Cell Biochem. 2017 Dec;118(12):4558-4567. doi: 10.1002/jcb.26117. Epub 2017 Jun 1.


Host Serine/Threonine Kinases mTOR and Protein Kinase C-α Promote InlB-Mediated Entry of Listeria monocytogenes.

Bhalla M, Law D, Dowd GC, Ireton K.

Infect Immun. 2017 Jun 20;85(7). pii: e00087-17. doi: 10.1128/IAI.00087-17. Print 2017 Jul.


The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.

Espinoza JL, Elbadry MI, Taniwaki M, Harada K, Trung LQ, Nakagawa N, Takami A, Ishiyama K, Yamauchi T, Takenaka K, Nakao S.

Cancer Lett. 2017 Aug 1;400:127-136. doi: 10.1016/j.canlet.2017.04.027. Epub 2017 Apr 26.


The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.

Miyahara H, Yadavilli S, Natsumeda M, Rubens JA, Rodgers L, Kambhampati M, Taylor IC, Kaur H, Asnaghi L, Eberhart CG, Warren KE, Nazarian J, Raabe EH.

Cancer Lett. 2017 Aug 1;400:110-116. doi: 10.1016/j.canlet.2017.04.019. Epub 2017 Apr 25.

Supplemental Content

Support Center